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Background: Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in
many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this
study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor
subtypes and survival in breast cancer patients.
Methods: Clinical-pathological information and follow-up data were collected from nine breast cancer studies from
the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients
with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of immunohistochemical
staining in tumor cells. Survival analyses were performed using a multivariable Cox model.
Results: The frequency of ANXA1 positive tumors was higher in familial breast cancer patients with BRCA1/2 mutations
than in BCAC patients, with 48.6 % versus 12.4 %, respectively; P <0.0001. ANXA1 was also highly expressed in BCAC
tumors that were poorly differentiated, triple negative, EGFR-CK5/6 positive or had developed in patients at a young age.
In the first 5 years of follow-up, patients with ANXA1 positive tumors had a worse breast cancer-specific survival (BCSS)
than ANXA1 negative (HRadj = 1.35; 95 % CI = 1.05–1.73), but the association weakened after 10 years (HRadj = 1.13;
95 % CI = 0.91–1.40). ANXA1 was a significant independent predictor of survival in HER2+ patients (10-years BCSS:
HRadj = 1.70; 95 % CI = 1.17–2.45).
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Conclusions: ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated
with poor prognosis features: triple negative and poorly differentiated tumors. ANXA1 might be a biomarker
candidate for breast cancer survival prediction in high risk groups such as HER2+ cases.
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Breast cancer is a heterogeneous group of pathologic
entities with different risk of recurrence and therapy re-
sponse [1]. In order to improve breast cancer diagnosis
and treatment decision, it is necessary to gain a better
understanding of the metastatic pathways and etiology.
Annexin A1 (ANXA1) protein binds the cellular mem-
brane phospholipids in a Ca2+ regulated manner and
can be phosphorylated on several residues both on the
N-terminal functional domain and on the C-terminus
core [2] by different proteins, such as the epidermal
growth factor receptor (EGFR) [3], insulin receptor (IR)
[4], TRPM7 channel kinase 1 (ChaK1) [5], protein kinase
C (PKC) and protein kinase A (PKA) [6]. ANXA1 has
been found in several tissues and regulates physiological
mechanisms such as hormone secretion [7], EGFR deg-
radation [8], membrane transport [9], apoptosis [10] and
cell differentiation [11]. As a glucocorticoid-induced mol-
ecule, ANXA1 plays an important role in the inflamma-
tory response [12].
ANXA1 expression is related with the carcinogenesis
process [13–15] and with metastasis formation in many
tumors [16–18], including breast tumors [19–23], where
we and others have shown that ANXA1 overexpression
is associated with high pathological differentiation grade,
lack of hormone receptor expression and a basal-like
phenotype [20, 24, 25]. Patients with BRCA1 or BRCA2
(BRCA1/2) germline mutations often present tumors
with these characteristics, but until now there are no
data in the literature implicating a link between high
ANXA1 expression and familial breast cancer. The main
focus of this study was to analyze the relationship be-
tween high ANXA1 tumor expression with BRCA1/2
germline carriership and survival in breast cancer pa-
tients, including those with specific tumor subtypes,
using a large dataset of pooled breast cancer series.
These analyses allow us to explore the potential of
ANXA1 as a marker for breast cancer outcome predic-
tion and treatment response.Methods
Study populations
The international Breast Cancer Association Consortium
(BCAC) comprises a large number of studies investi-
gating the role of common germline genetic variation
in breast cancer susceptibility [26]. Nine studies fromEurope, North America, New Zealand and Australia
contributed with 8,182 cases to this ANXA1 study
(Additional file 1: Table S1). All studies were approved
by the relevant ethics committees and informed con-
sent was obtained from all participants (Additional file 1:
Table S1). Clinical-pathological information and follow-
up data were collected by each study individually through
medical records, cancer registries and cause of death
registries. Data were pooled in the BCAC database ac-
cording to a data dictionary, and centrally checked for
accuracy and consistency. Data included were: age at
diagnosis; behavior (in situ or invasive); morphology
(ductal, lobular and others); tumor size (≤2 cm, >2
and ≤5 cm, or >5 cm); differentiation grade (1, 2 or 3);
lymph node status (negative or positive); and breast cancer
treatment (radiotherapy, hormonal therapy and chemo-
therapy). The most common source of data for ER, PR
and HER2 status was from medical records, followed by
immunohistochemistry (IHC) performed on tumor tissue
microarrays (TMAs) or whole section tumor slides. The
subtypes were defined as follows: luminal 1 (ER+ and/or
PR+ and HER2-); luminal 2 (ER+ and/or PR+ and
HER2+); HER2-like (ER-, PR- and HER2+); and triple
negative (ER-, PR- and HER2-). Data on CK5/6 and EGFR
tumor status were derived from IHC performed on TMAs
or whole sections detailed previously [27]. The p53 staining
data (received only from one breast cancer study) and the
BRCA1 and BRCA2 status mutation of the BCAC patients
were obtained as described previously [28, 29]. A specific
cohort of 132 BRCA1/2 mutated (BRCA1|2), familial
breast cancer patients (a minimum of three first- or
second-degree relatives affected with breast and/or ovarian
cancer in a family) were included from the Helsinki
University Central Hospital (HUCH) in southern Finland
as described previously [30]. In addition, within the BCAC
there were a few cases from some studies known to be
BRCA1/2 mutated and we excluded these for the analyses
comparing BCAC with BRCA1|2 tumors.ANXA1 staining
Ninety TMA slides from 8,705 patients were received
for ANXA1 staining (including 1 to 6 tumor cores per
patient). The ANXA1 staining was performed at the
Core Facility Molecular Pathology and Biobanking
(CFMPB) at the NKI-AVL on a BenchMark ULTRA auto-
stainer (Ventana Medical Systems, Tucson, AZ, USA).
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and deparaffinized in the instrument with EZ Prep solution
(Ventana Medical Systems). Heat-induced antigen retrieval
was carried out using Cell Conditioning 1 (CC1; Ventana
Medical Systems) for 64 min at 95 °C. ANXA1 was
detected by incubating sections with antibody clone
29/Annexin I (610066; BD Transduction Laboratories,
Franklin Lakes, NJ, USA), 1/1500 dilution for 1 h. Specific
reactions were detected using ultraView Universal DAB
Detection Kit (Ventana Medical Systems) and slides were
counterstained with hematoxylin.
The ANXA1 expression in tumor cells was scored only
if the spot was evaluable, subjectively defined as approxi-
mately more than 30 % of tumor cells present in the
spot. ANXA1 is also expressed in stromal cells but this
was not included in the evaluation. Three variables were
evaluated: intensity of the staining (negative, weak,
moderate or strong); cellular location of the staining
(cytoplasm and nucleus or only in cytoplasm); and the
percentage of stained cells (0 % to 100 %). Scores were
categorized as: 0, no expression; 1+, 10 % to 30 %
stained; 2+, 40 % to 70 %; and 3+, 80 % or more cells
stained (Additional file 2: Figure S1). The intensity of
the staining and the cellular location scores did not con-
tribute to the discernment of different groups by
ANXA1 stains and therefore were not further used in
the analysis (Additional file 3: Figures S2A and S2B).
Evaluation of ANXA1 expression levels were per-
formed by MdG with consultation of three pathologists
(JW, JS and VTS). The concordance was around 81.7 %
and 92.4 % among all of them, considering 0 or 1+ as
negative and 2+ or 3+ as positive, with a kappa value
of 0.86, considering positive versus negative cases be-
tween MdG and JW. A subset of 452 patients in the
previously published ABCS study were rescored for
this study [24].
Around 20 % (n = 2,124) of the included patients en-
rolled in TMA constructions could not be scored due to
technical problems (no sample or less than 30 % of
tumor cells in the spot), but the clinical-pathological
variable distributions did not differ between patients
with or without ANXA1 scores (Additional file 4:
Table S2). For analyses, we clustered 0 and 1+ groups
based on previous experience [24]. Of note, overall survival
(OS) and breast cancer-specific survival (BCSS) did not
differ between the 0 and 1+ groups nor between the 2+
and 3+ groups (Additional file 3: Figures S2C and S2D).
Statistical analyses
In total, we included 6,177 patients for descriptive ana-
lysis. For association and survival analysis, the in situ
breast cancer cases were excluded (n = 204). Patients diag-
nosed with distant metastases at diagnosis of the primary
tumor (n = 31) and those who received chemotherapybefore the surgery (n = 84) were also excluded (Additional
file 5: Figure S3).
In the case of significant associations between ANXA1
expression and a histopathological variable as evaluated
by the Chi-square test, the odds ratios (OR) and their
respective 95 % confidence intervals (95 % CI) adjusted
for independent clinical variables (ORadj) were assessed
using logistic regression models. The ANXA1 expression
was tested for linear-by-linear associations to calculate
trend significances (Ptrend) between tumor subtypes in
Fig. 1. The statistical association analyses were con-
ducted using SPSS 20 (SPSS Inc., Chicago, IL, USA).
Survival time was calculated from date of diagnosis to
date of death/censoring. In order to allow for prevalent
cases, time at risk was calculated from date of study
entry to date of death/censoring. This generates an un-
biased estimate of the hazard ratio (HR) provided the
Cox proportional hazards assumption holds [31]. End of
follow-up was defined as the date of (breast cancer)
death, last follow-up or 10 years, whichever came first.
Distant metastasis-free survival (DMFS) analysis was
performed as well, with time censored at 5 years. HRs
were estimated using Cox regression models, stratified
by BCAC studies. Multivariate Cox models were fitted
including the variables associated with breast cancer
prognosis: age at diagnosis as continuous variable; tumor
grade (1, 2 or 3); tumor size (≤2 cm, >2 cm and ≤5 cm,
or >5 cm); lymph node status (negative versus positive);
ER/PR status (ER and PR negative versus ER or PR
positive); and HER2 receptors status (negative versus
positive) as categorical covariates. The analyses were
performed as a complete case analysis and a second-
ary analysis was performed including the missing
values in the model. ER/PR status was included as a
time-varying covariate because of violation of the
proportional hazards assumption using the Schoenfeld
residuals test in the multivariable model (P <0.0001). Ad-
justment for chemotherapy and/or hormonal therapy did
not significantly change the results and these were not
included in the final models. All P values reported are
from two-sided tests and the threshold for significance
was set at P = 0.05. The survival analyses were performed
using STATA version 11.0 (StataCorp, TX, USA).
Results
Analyses included 5,752 patients from BCAC cohorts,
including cases not known to be BRCA1/2 carriers, and
107 breast cancer patients from one study of familial
breast cancer patients with BRCA1/2 mutations (Table 1;
Additional file 4: Table S2; Additional file 5: Figure S3).
ANXA1 expression in breast cancer patients
The distribution of patients and tumor characteristics
of BCAC and BRCA1/2 mutated patients is shown in
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Fig. 1 ANXA1 expression profile. Percentage of patients with ANXA1 positive tumors according to breast cancer subtypes comparing BCAC
(excluding 37 patients with BRCA1 or BRCA2 mutations) versus BRCA1/2 mutation carriers. For the subtype analysis, patients with missing information
for ER, PR and/or HER2 were excluded (393 in BCAC and 36 in BRCA1/2 mutation carriers). Luminal 1 subtype was defined as ER+ and/or PR+ and
HER2-, and triple negative (TN) was defined as ER-, PR- and HER2-. Numbers of HER2+ were too small in the BRCA1/2 mutation carriers to
make a comparison. ANXA1: Annexin A1; BCAC: Breast Cancer Association Consortium; TN: Triple negative
Sobral-Leite et al. BMC Medicine  (2015) 13:156 Page 4 of 11Table 1. Younger patients (<50 years old) had slightly
more often ANXA1 positive tumors compared with the
older group (≥50 years old), in both subsets of patients.
Poorly differentiated (high grade) tumors were associ-
ated with ANXA1 positive expression (tumor grade 2
or 3: ORadj = 1.59; 95 % CI = 1.04–2.43); as well as those
positive for basal-like markers (EGFR and/or CK5/6
positive) or triple negative (ORadj = 4.21; 95 % CI = 3.22–
5.50 and ORadj = 6.01; 95 % CI = 4.61–8.01, respectively)
(Additional file 6: Table S3).
ANXA1 expression was higher in the tumors from
BRCA1/2 mutated patients compared to BCAC patients
overall: 48.6 % versus 12.4 %, respectively; P <0.0001,
and within specific breast cancer subtypes (Fig. 1).
Although all BRCA1/2 mutated carriers were only from
Finland, the proportion of ANXA1 positives in the
Finnish BCAC study (HEBCS) was the same compared
to that of other BCAC studies (Additional file 1:
Table S1A). Triple negative tumors in BRCA1/2 mu-
tated carriers showed a higher ANXA1 expression
than triple negative breast cancer patients in the BCAC
cohort (84.2 % versus 41.9 %, respectively; P <0.0001).
Also, there was a trend for higher ANXA1 expression
with a decrease in hormone receptor positivity (i.e. sub-
types ranging from luminal to HER2+ to triple negative;
Ptrend <0.0001) (Fig. 1). Moreover, the BRCA1 patients
presented a slightly higher expression of ANXA1 com-
pared with BRCA2 mutated patients (57.6 % versus
37.5 %, respectively; P = 0.0583) (Table 1). In BRCA1/2
mutated patients, ANXA1 expression was associated withp53 positive status (ORadj = 14.97; 95 % CI = 1.38–163.49;
Additional file 6: Table S3).
Survival analysis according to ANXA1 expression
We performed survival analysis of all BCAC patients
with follow-up information (follow-up mean: 8.9 years).
Patients with ANXA1 positive tumors showed a
worse survival than the ANXA1 negative ones, both
for OS (Fig. 2a; P = 0.0004) and BCSS (Additional file 7:
Figure S4A; P <0.0001). Similar trends of worse survival
were seen in the nine separate cohorts, except for
MCBCS (data not shown). After adjustment for clinical
variables, a significant association between ANXA1 posi-
tivity and worse survival was observed only during the
first 5 years of follow-up, but not after 10 years of follow-
up (5-years BCSS: HRadj = 1.35; 95 % CI = 1.05–1.73 and
10-years BCSS: HRadj = 1.13; 95 % CI = 0.91–1.40; see
also Additional file 8: Table S4). The strong association
of ANXA1 expression with poorly differentiated grades
and triple negative status likely contributed to this lack of
association after 5 years. Similar time-dependent differ-
ences in survival were observed in lymph node positive
patients (Fig. 2d and Additional file 7: Figure S4D), but
ANXA1 expression did not influence survival in lymph
node negative patients (Fig. 2c and Additional file 7:
Figure S4C).
Evaluating the tumor subtypes, ANXA1 high ex-
pression was specifically associated with an increased
mortality in HER2 positive patients (10-years OS:
HRadj = 1.60; 95 % CI = 1.06–2.41 and 10-years BCSS:
Table 1 ANXA1 expression and clinical variables
BCAC patients BRCA1|2 mutation carriers
ANXA1 negative ANXA1 positive ANXA1 negative ANXA1 positive
n % n % P valuea n % n % P valueb P valuec
5,040 87.6 712 12.4 55 51.4 52 48.6 <0.0001
Age of diagnosis <0.0001 0.2253 0.0401
<50 years old 2,462 85.6 413 14.4 34 47.2 38 52.8
≥50 years old 2,578 89.6 299 10.4 21 60.0 14 40.0
Missing 0 0 0 0
BRCA status 0.0026 0.0583
Non-carrier 858 83.6 168 16.4
BRCA1 11 61.1 7 38.9 25 42.4 34 57.6
BRCA2 14 73.7 5 26.3 30 62.5 18 37.5
Missing 3,812 430 0 0
Menopausal status 0.0330
Pre- 1,556 86.2 250 13.8
Post- 2,258 88.3 298 11.7
Missing 1,226 164
Morphology <0.0001 0.5946 0.0235
Ductal 3,558 86.2 568 13.8 33 50.8 32 49.2
Lobular 710 94.3 43 5.7 11 61.1 7 38.9
Missing 772 101 11 13
Grade <0.0001 0.0040 0.1460
1 1,129 95.0 59 5.0 7 77.8 2 22.2
2 2,246 92.8 173 7.2 26 66.7 13 33.3
3 1,306 75.2 431 24.8 19 35.8 34 64.2
Missing 359 49 3 3
Tumor size <0.0001 0.9910 0.7780
≤2 cm 2,809 88.8 354 11.2 31 51.7 29 48.3
>2 cm and ≤5 cm 1,610 86.5 252 13.5 19 52.8 17 47.2
>5 cm 109 79.9 29 21.0 2 50.0 2 50
Missing 512 77 3 4
Node status 0.2725
Negative 2,669 87.1 395 12.9 31 47.0 35 53.0 0.3044 0.1790
Positive 1,955 88.1 263 11.9 22 59.5 15 40.5
Missing 416 54 2 2
ER status <0.0001
Negative 977 67.8 465 32.2 13 28.3 33 71.7 <0.0001 0.7373
Positive 3,796 95.0 200 5.0 36 75.0 12 25.0
Missing 267 47 6 7
PR status <0.0001
Negative 1,435 75.9 455 24.1 20 35.1 37 64.9 <0.0001 0.1670
Positive 3,159 94.8 175 5.2 27 77.1 8 22.9
Missing 446 82 8 7
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Table 1 ANXA1 expression and clinical variables (Continued)
HER2 status 0.1328
Negative 3,484 88.7 442 11.3 25 48.1 27 51.9 1.0000 0.0684
Positive 643 86.8 98 13.2 1 50.0 1 50.0
Missing 913 172 29 24
EGFR-CK5/6 statusd <0.0001
Negative 3,317 93.8 218 6.2
Positive 541 67.6 259 32.4
Missing 1,182 235
p53 statuse 0.0572
Negative 172 90.1 19 9.9 17 45.9 20 54.1 0.0211 0.8116
Positive 57 80.3 14 19.7 3 14.3 18 85.7
Missing 596 89 35 14
Adjuvant chemotherapy <0.0001
No 2,593 89.9 282 10.1
Yes 1,585 83.2 320 16.8
Missing 862 100
Adjuvant hormonal therapy <0.0001
No 2,059 82.5 438 17.5
Yes 2,562 92.6 204 7.4
Missing 419 70
Distribution of the clinical variables in breast cancer patients according to the ANXA1 expression in all invasive tumors from the BCAC and BRCA1|2 set of patients
ANXA1 annexin A1, BCAC Breast Cancer Association Consortium, EGFR epidermal growth factor receptor
aP value of the comparison between ANXA1 positive and negative patients in the BCAC set
bP value of the comparison between ANXA1 positive and negative patients in the BRCA1|2 mutated set
cP value of the comparison between the two sets of ANXA1 positive patients: BCAC and BRCA1|2 mutated patients
dEGFR-CK5/6 status was defined as positive when CK5/6 and/or EGFR were positive
ein the BCAC set, p53 status information was only available for the ABCS study
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file 7: Figure S4B). The P values for interaction between
ANXA1 and HER2 in a full model for BCSS or OS, in-
cluding HER2 positive and negative cases, were 0.136
and 0.140, respectively. In addition, ANXA1 positive
cases showed a slightly worse survival in the subgroup of
patients older than 49 years old, which seemed to be re-
lated to menopausal status (data not shown). For none of
the subgroup analyses the DMFS was significantly differ-
ent between ANXA1 high and low expression groups.
ANXA1 expression and treatment response
In order to explore the value of the ANXA1 expression
in therapy resistance, we performed survival analyses in
the group of patients who received adjuvant chemother-
apy, as currently recommended. Using clinical guidelines
[32], the BCAC patients were classified according to the
risk of recurrence using classic prognostic factors for de-
termining the chance of distant metastases occurrence.
Within the group that received adjuvant chemotherapy,
patients with high risk of recurrence (HER2+ and/or pN
+) showed a slightly worse OS and BCSS when ANXA1
was positive, compared with the ANXA1 negative onesin the group aged 50–69 years only (BCSS HRadj = 2.02;
95 % CI = 1.21–3.36 and HRadj = 1.41; 95 % CI = 0.80–
2.50; Additional file 9: Figure S5).
Part of these patients (24.2 %) received anthracycline-
based adjuvant chemotherapy. In the same high risk
group aged 50–69 years, the ANXA1 positive cases pre-
sented a suggestive worse outcome after anthracycline-
based adjuvant chemotherapy (10-years OS: HRadj = 2.48;
95 % CI = 0.82–7.50; Fig. 3 and BCSS: HRadj = 2.96;
95 % CI = 0.92–9.57; Additional file 7: Figure S4F).
Discussion
Here, for the first time, the ANXA1 expression in a sub-
set of BRCA1/2 mutated carriers is described. We found
a significantly higher expression of ANXA1 in tumors
from familial breast cancer patients with BRCA1/2 mu-
tations compared with hospital and population-based
breast cancer series.
We also found a higher ANXA1 expression in triple
negative patients, confirming previous studies [20, 24,
25]; association with poor differentiation grade is also
described in other types of cancers [33, 34]. The associ-
ation between ANXA1 expression and basal markers
Fig. 2 Survival analysis. Survival curves, crude hazard ratios (HR) and adjusted hazard ratios (HRadj) in patients from BCAC according to ANXA1
expression for overall survival in (a) all BCAC patients, (b) HER2 positive patients, (c) lymph node negative patients and (d) lymph node positive
patients. Hazard ratios were adjusted for: age of diagnosis; tumor grade; tumor size; lymph node metastasis; ER/PR status; and HER2 status.
ANXA1: Annexin A1; BCAC: Breast Cancer Association Consortium; HR: Hazard ratio
Fig. 3 Adjuvant treatment response. Survival curves, crude hazard ratios (HR) and adjusted hazard ratios (HRadj) according to ANXA1 expression in
patients from BCAC with high risk of recurrence (HER2+ and/or pN+) who received anthracycline-based adjuvant chemotherapy. Overall survival
and disease-free survival in (a, b) patients under 50 years old and (c, d) patients over 49 and under 70 years old. Hazard ratios were adjusted for:
age of diagnosis; tumor grade; tumor size; lymph node metastasis; ER/PR status; and HER2 status. Note: low risk of recurrence was defined as:
35 years old or older; lymph node negative; tumor size ≥2 cm with any grade or tumor size ≥1 cm with tumor grade ≥2; high risk of recurrence
was defined as: HER2+ and/or lymph node positive. ANXA1: Annexin A1; BCAC: Breast Cancer Association Consortium; HR: Hazard ratio
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in our previous work using a smaller cohort of breast
cancer patients [24], suggesting that ANXA1 may play a
role in EGFR trafficking [8, 35]. Moreover, the higher
frequency of ANXA1 expression in younger patients is
not surprising since this group develops more often tu-
mors of poor differentiation grade, triple negative status
or with basal marker overexpression [36].
The BRCA1/2 mutated patients belong to a group that
already contains a high number of triple negative and
basal-like breast cancers [37], but here we showed that
triple negative tumors in BRCA1/2 mutated carriers are
even more highly expressing ANXA1 than triple nega-
tive patients in the BCAC cohort (Fig. 1). Perhaps such
differences may involve the p53 expression, which was
higher in the ANXA1 positive tumors (Additional file 6:
Table S3). The tumor suppressor gene TP53 is more
commonly altered in BRCA1/2-related breast cancers, as
measured either by IHC or mutation analysis [38]. In-
deed, in vitro studies in colon cancer cells suggest the
existence of a binding site for p53 in the promoter of
the ANXA1 gene, inducing its expression and phosphor-
ylation [39, 40]. Unfortunately, the group of BRCA1/2
mutated carriers presented here is small, indicating that
other studies focused in the ANXA1 expression profile
in this group of patients are required.
In the survival analysis, ANXA1 positive tumors were
independently associated with OS and BCSS in the first
5 years, but not in years 5 to 10. Findings of OS and
BCSS were in line, signaling that a significant proportion
of the patients with breast cancer died from it and not
from other causes, which is expected especially since this
series included a large proportion of relatively young
breast cancer patients (Additional file 7: Figure S4). We
had observed some indication for time dependency of
ANXA1. Including ANXA1 time dependency in the
model, we even found a suggestion of better survival in
the ANXA1 positive group in the 5- to 10-year period of
follow-up (BCSS: HRadj = 0.65; 95 % CI = 0.40–1.03). For
ANXA1 gene expression, using KM plotter [41], a
similar trend was seen with a worse recurrence-free
survival in the first 5 years (HR = 1.15; CI = 1.18–
10.29; P = 0.03), but not over the whole 10-year period
(HR = 1.08; CI = 0.96–1.21; P = 0.21).
In our data, specifically patients with HER2+ tumors
and ANXA1, overexpression showed a worse outcome,
even after 5 years (10-years BCSS: HRadj = 1.70; 95 %
CI = 1.17–2.45). This is in line with the finding from
Yom et al., who observed a worse recurrence-free sur-
vival for ANXA1 positive cases also in lymph node
positive and HER2+ patients [25]. Of note, most of the
cases in our study were not treated with trastuzumab
due to the period that they were diagnosed. Accord-
ingly, the absolute OS was lower than would beexpected after breast cancer treatment nowadays. Even
so, the worse relative survival seen in our study is still
relevant for HER2+ patients though with some caution
because in most countries nowadays HER2+ patients
are also treated with trastuzumab. Further research is
therefore warranted to investigate the potential of
ANXA1 as a predictor of trastuzumab resistance.
Of note, we observed some heterogeneity between the
BCAC studies for the percentage of annexin A1 positive
tumors (Additional file 1: Table S1A). These did not
seem to be fully explained by differences in tumor char-
acteristics (data not shown) and since the staining was
done centrally there might have been some influence of
the age of the tumor material and/or fixation at the time
of embedding.
We also observed that ANXA1 overexpression was as-
sociated with worse survival in patients with high risk of
recurrence in an age-dependent manner, with worst out-
come in premenopausal patients, especially in the group
that received anthracycline-based adjuvant chemother-
apy. Unfortunately, for many cases, information about
the type of chemotherapy was missing. Therefore, this
might be due to chance and hypothesizing a mechanism
for these findings is difficult. However, Ang et al. sug-
gested that ANXA1 can regulate growth arrest induced
by high levels of estrogen [42], which is the typical
physiological condition in premenopausal women. To
our knowledge there are no other studies that evaluated
ANXA1 expression and anthracycline-based chemother-
apy resistance. ANXA1 overexpression was associated
with cisplatin resistance in lung adenocarcinoma [43],
radiotherapy and chemotherapy resistance in naso-
pharyngeal carcinoma [44], worse chemotherapy re-
sponse after treatment with docetaxel, cisplatin and
5-fluorouracil in oral squamous cell carcinoma [34],
and poor response after neoadjuvant treatment with taxo-
tere and carboplatin in triple negative breast cancer [45].
Although ANXA1 has been described to play a role in
metastasis formation in breast cancer [46], the exact
mechanism remains unknown. ANXA1 being also
expressed in normal myoepithelial cells, the loss of
ANXA1 expression in breast carcinomas has been de-
scribed as a stage of malignant transformation [19, 20, 47].
In breast cancer models, ANXA1 has been shown to
modulate cell adhesion and motility [23] by TGFβ-
mediated EMT-like switch [24] and by matrix
metalloproteinase-9 regulation via NF-κB [21, 48], but
another study found conflicting evidence [49]. Moreover,
as a glucocorticoid-induced protein, ANXA1 might
also be able to provide critical interference in the
tumor stroma and its microenvironment cross-talk [17].
Altogether, our findings stress the importance of ANXA1
for prognosis and possibly for therapy resistance in
breast cancer. We are also the first to show that there
Sobral-Leite et al. BMC Medicine  (2015) 13:156 Page 9 of 11is a link between BRCA1/2 mutations and ANXA1
overexpression.
Conclusion
We conclude here that ANXA1 expression is associated
with tumors with selected well-known poor prognosis
characteristics (e.g. poor differentiation grade, triple
negative, BRCA1/2 mutations). Our survival analysis
showed that ANXA1 expression in breast tumors might
be a biomarker candidate for breast cancer outcome
prediction in high risk groups such as HER2+ cases,
playing a complex role in chemotherapy resistance. Fur-
ther studies are needed to elucidate whether ANXA1 is
indeed a prognostic factor or may be used to predict
chemotherapy response.
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